Merck & Co., Inc. (MRK) Earnings Call Transcript & Summary

July 29, 2021

New York Stock Exchange US Health Care Pharmaceuticals earnings 70 min

Earnings Call Speaker Segments

Peter Dannenbaum

executive
#1

Thanks, Mary, and good morning. I want to welcome everyone to the conference call for Merck's second quarter of 2021. Joining me on this call are Rob Davis, who serves as our Chief Executive Officer, Dr. Dean Li, who is President of Merck Research Labs, Frank Clyburn, President of Human Health, and Caroline Litchfield, our Chief Financial Officer. Before we begin, I want to highlight a few things. You'll notice that our GAAP results include certain items, including acquisition-related charges, restructuring costs, and some other items. Please be aware that these have been excluded from our non-GAAP results, and a reconciliation is available in our press release. I also want to remind everyone that a number of the remarks we make on today's call could be deemed forward-looking statements under the Safe Harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. These statements reflect Merck management's current beliefs and carry significant risks and uncertainties. Should our underlying assumptions turn out to be inaccurate, or should uncertainties come to pass, actual results could differ materially from what those forward-looking statements set forth. Our SEC filings, including Item 1A in the 2020 10-K, lay out certain risk factors and cautionary statements that might cause the company's actual results to differ materially from those projected in any forward-looking statements we make this morning. Merck has no obligation to publicly update any forward-looking statements. Our SEC filings, today's earnings release, and an investor presentation highlighting our results are all available on merck.com. With that, let me hand the call over to Rob.

Rob Davis

executive
#2

Thank you, Peter. Good morning to all of you. It's a tremendous privilege to address you today in my new capacity as CEO. Merck is an extraordinary organization, and I feel very lucky to be working alongside skilled and committed team members who are sharply focused on delivering vital medicines and vaccines that enhance and save lives for people and animals across the globe. This deep and steadfast dedication to our mission is genuine, it's concrete, and it's what pushes us to excel each day. The emphasis placed on funding research and development during Ken's tenure, along with concentrating resources on key growth drivers, has left us in a strong position that I plan to strengthen further. When I think about what lies ahead for Merck, I remain convinced that putting investment into research and development with patients at the heart of all we do is fundamental to Merck's identity and represents our surest route to lasting, continuous achievement and the creation of value. That said, the way we pursue the finest scientific possibilities both outside and within our walls, and the way we deliver those breakthroughs to patients, has to change. When I stepped into the CEO position, I sought honest input from my colleagues and from external partners. What I learned confirmed my beliefs. There is widespread consensus that spending on R&D ought to stay our top strategic priority. Our people are certain we're headed in the right direction. We have rebuilt and re-energized our discovery research engine and possess an expanding and strong pipeline. We're carrying out clinical development effectively, and we're achieving robust commercial growth in both our Human and Animal Health businesses at present and will keep doing so far into the future. Even though we're on the right track, we must operate with greater speed, urgency, and agility, keeping pace more closely with how quickly the broader environment is changing. We must speed up the delivery of our breakthroughs to the patients who need them and become leaner, more nimble, and more digitally empowered. We must take advantage of the scale and reach that come with being a worldwide biopharmaceutical leader while also committing to adapt in order to meet new challenges, and we must proceed with focus and deliberate purpose, which is a priority for me and for my management team alike. I recognize that it isn't about making promises, it's about delivering results. Actions speak louder than words. With that in mind, I commit to doing everything within my power to make certain Merck stays a worldwide biopharmaceutical leader well into the future, generating value for today's and tomorrow's patients as well as growth and value for our shareholders. Now, let me turn to the quarter. We delivered very solid results with robust growth. Our numbers show that the pandemic's effect on our business is diminishing. Patients' access to healthcare providers has gotten better, and we anticipate sustained strong growth for the rest of the year. We're also achieving significant clinical progress, which Dean will discuss in just a few moments. The fact that we carried out a complicated spin-off with no disruption to the business, went through changes in leadership, and still delivered faster growth during this stretch only strengthens my belief in what this organization is capable of going forward. Organon now stands as a standalone entity, a significant landmark in the story of our company. This deal serves as a powerful catalyst for Merck to become a business that is more focused, more efficient, and growing at a quicker pace. Let me take a moment to discuss KEYTRUDA, which once again saw very robust growth in this quarter. My conviction is firm that KEYTRUDA will remain a foundational cancer therapy and deliver strong growth for many years ahead. We hold a leading position in immuno-oncology and are committed to turning that into lasting success; we are moving quickly to advance a varied set of oncology assets, a number of which we showcased during our recent ASCO investor presentation. Throughout our oncology portfolio, we anticipate more than 90 potential new indications by 2028. That's more than triple what we have today. We possess a broad range of clinical partnerships that give us valuable understanding of disease biology and of significant potential external innovation. With our growing oncology portfolio beyond KEYTRUDA, we will carry our cancer leadership far into the future. I am also firmly convinced we will steer successfully through the eventual loss of exclusivity for KEYTRUDA, because of the wide scope of opportunity in areas inside as well as beyond oncology. On the internal side, our leaders are sharply focused on this period, and work is already in motion. On the external side, I recognize how important it is to give investors greater transparency into the wide range of opportunities we see in our pipeline that will help us accomplish this. Just as we recently did in spotlighting islatravir, our broader HIV portfolio, and our next-generation oncology assets, we are arranging deep-dive investor events featuring our scientific and commercial leaders, centered on other parts of our pipeline that we feel are underappreciated yet hold great promise, like our suite of vaccine candidates, our cardiometabolic assets, and others too. Business development has a key role to play, and we are placing greater emphasis on making sure we are appropriately aggressive when it comes to accessing the best external science. Carrying out value-enhancing BD ranks as a top priority, and we plan to add to our pipeline via acquisitions, partnerships, licensing deals, and collaborations; we will not be constrained by therapeutic area, though we remain mindful of the need for a balanced portfolio over time. We'll pursue new products, modalities, and platforms that let us establish beachheads in important areas. Our recent acquisition of Pandion and its potentially foundational immunology asset is a solid illustration of this. We will evaluate both early and late-stage opportunities, and we have the financial flexibility to consider deals of all sizes, especially in light of the $9 billion distribution from the Organon spin-off. Because of our strong operational momentum, we are most interested in transactions that are easily integrated and less disruptive, where value comes principally from the introduction of innovative new products that address patient needs rather than through cost synergies. Prior to handing things over to Frank so he can go through how our Human Health segment did in the second quarter, I'd like you to hear that I welcome and cheer the growing pressure from society and investors for companies to behave responsibly. Across environmental, social, and governance matters, I think the results we've delivered are strong and have been generating lasting worth for every one of our stakeholders, and that will keep being the case. Strong corporate citizenship is something Merck has demonstrated over a lengthy history and record, and staying a leader here is something I'm dedicated to. So with that said, I'll pass the call to Frank.

Frank Clyburn

executive
#3

Thanks, Rob, and good morning, everyone. Rob already noted that things are picking up once more in our Human Health business, and this quarter we posted an 18% increase when you strip out currency effects. Across the whole organization, we've been acting fast on spending designed to push doctor's office visits, cancer screenings, and immunization rates—shots for people who fell behind included—back up toward where they normally sit. Our colleagues around the globe have proven nimble at redirecting people and money toward these patient activation programs, and that's delivered results for a portfolio where physicians handle most of the administering; here in the U.S., it's a good sign that routine checkups and operations are once again close to standard levels. Turning to oncology, we're seeing screening rates continue to rise, and we believe those encouraging trends, along with solid demand beneath the surface for our offerings, will drive quicker underlying business momentum in the back half of this year. Next, I want to walk through how our main brands did in Q2. Everything I say will be on an ex-exchange basis. Starting with oncology, KEYTRUDA sales grew 20% to $4.2 billion, reflecting continued strong demand globally. Within the U.S., KEYTRUDA continues to deliver strong growth and has been picking up share among new patients in immuno-oncology throughout the pandemic. KEYTRUDA also remains number one in lung cancer, where it captures eight of every 10 eligible new patients. We continue seeing robust expansion in every major tumor type, including renal cell carcinoma, bladder cancer, adjuvant melanoma, and the MSI-high indication we serve. In addition, the KEYNOTE-355 launch for metastatic triple-negative breast cancer has gotten off to an excellent start, and we expect to add overall survival to its label. We're equally excited about the newly approved KEYNOTE-522 and its upcoming launch in the neoadjuvant and adjuvant settings. Outside the U.S., indications in lung cancer, plus launches still underway in head and neck cancer and renal cell carcinoma, continue driving our growth. LYNPARZA climbed 34% during the quarter and remains the leading PARP inhibitor. New indication clearances keep fueling expansion, and we look forward to what could be a forthcoming introduction in adjuvant breast cancer, based on the OlympiA findings presented at ASCO this year. LENVIMA climbed 15% during the quarter, reflecting stronger demand for hepatocellular carcinoma following its NRDL inclusion in China. In addition, we are keen to roll out the newly cleared combination of LENVIMA and KEYTRUDA for endometrial carcinoma, and soon after, possibly bring it to market for renal cell carcinoma, supported by KEYNOTE-581. Our vaccines business rebounded dramatically as wellness visits returned closer to normal levels. GARDASIL delivered an exceptionally robust quarter, rising 78%; in the U.S., the sales increase stemmed from recovery after the adverse impact of last year's lockdowns. Beyond the United States, greater demand in China fueled growth. Sales also got a boost from increased supply thanks to better manufacturing, which I'll say more about shortly. Our hospital business kept recovering. BRIDION's sales were up 67% compared to the same period a year ago, fueled by a rise in surgical procedures as patients' ability to reach hospitals got better versus last year. Now for our outlook: the rebound we witnessed during the quarter makes us confident about delivering a very strong second half, coming from both a recovering market and solid commercial execution. During the quarter, Merck moved quickly, shifting its attention and resources toward campaigns aimed at activating patients, to make certain patients are prioritizing their health and understanding how important it is to go back to doctors' offices for screenings, early detection, and routine visits. What we've done alongside public health constituent groups, combined with the ongoing rollout of COVID-19 vaccinations, has produced meaningful gains in patients getting to healthcare providers. Among adolescents, over 1/3 of teens in the United States have received at least one dose of a COVID-19 vaccine. We're assuming these fast-rising vaccination rates, together with continued commercial execution, will help bring about a near normal back-to-school season. Merck has also shown it can move faster and operate more efficiently across the whole company, and what matters is that the gains we've made will open the door to substantial growth ahead. One clear example: we expect GARDASIL to benefit a great deal as our supply chain becomes more productive, allowing us to meet demand we previously couldn't fill. On top of that, because demand for GARDASIL around the world continues to outstrip what we can provide, our teams have been pursuing the necessary regulatory clearances and lead time so doses can be directed appropriately to the regions where need has grown — all the more so as the pandemic continues to impose lockdowns in many places. Those improvements alone should drive quite robust sequential and year-over-year growth for GARDASIL during the second half of the year, above all outside the U.S. When it comes to markets like China, and specifically within oncology, the rebound we've witnessed to this point is encouraging, as is how we performed overall during the pandemic. Our confidence remains solid regarding the fundamental demand for our extensive, innovative lineup — this includes KEYTRUDA, LYNPARZA, LENVIMA and, should it gain approval, belzutifan — and we anticipate delivering robust, enduring expansion across major tumor types and disease stages. Taking everything into account, the improvements in patient access we're observing across key markets leave us feeling more assured as we head into the latter half of the year. Before I finish, I'd like to recognize how well our commercial teams worldwide performed, which enabled the company to achieve significant growth during the first six months of the year, all while we're working toward the successful completion of the Organon spinoff. We believe this spinoff delivers substantial advantages to the commercial organization, among them the capacity to generate even greater growth by concentrating our commercial efforts more sharply. In conclusion, momentum has returned to our business, and we're positioned favorably to deliver robust growth across the third and fourth quarters. Our portfolio has come back strongly, showing both its resilience and the value it brings to patients everywhere. That significant rebound during the quarter reinforces how assured we are about the fundamental need for the new treatments and shots we produce, and we anticipate getting back to strong, durable growth propelled by that demand; having said that, I'll now hand things over to Caroline.

Caroline Litchfield

executive
#4

Thanks, Frank. Good morning, everyone. During the quarter, our business achieved significant growth, fueled by robust underlying demand for products within our growth pillars and by the ongoing rebound of the business as patient access got better. As we finish the quarter, we feel confident that our financially and operationally strong position will allow us to generate long-term revenue growth and substantial margin expansion, creating shareholder value as we fulfill our mission of improving the health and wellness of people and animals around the world. Now let's discuss our second quarter results, which show Merck on a continuing operations basis. Revenues for the entire company came to $11.4 billion, up 22%, or 19% when you exclude the favorable foreign exchange impact. After also adjusting for the estimated pandemic impact, total revenues rose 8% compared with the prior year, demonstrating the underlying strength of our business. The rest of my remarks will use an ex-exchange basis. As Frank pointed out, our Human Health business demonstrated improving momentum, with growth of 18%, or 6% once adjusted for the estimated pandemic impact. Animal Health enjoyed an excellent quarter, rising 27%, propelled by extremely strong global demand across companion animal and livestock, which rose 38% and 20%, respectively. Animal Health sales were up 19% after adjustment for the estimated pandemic impact. Within companion animal, growth came from higher global demand for vaccines and parasiticides, including the Bravecto line of products. Livestock performance reflects greater global demand across ruminants, swine, and poultry products, plus stronger demand for our Animal Health Intelligence products. I'll now take you through the rest of our P&L. My comments will use a non-GAAP basis. Gross margin for the quarter was 76.5%, down 0.6%, which reflects unfavorable foreign exchange effects, pricing pressure, and higher manufacturing costs, partly offset by favorable product mix. Operating expenses rose 13% versus the prior year to $4.8 billion, mainly because of higher clinical development costs, greater investment in our early-stage pipeline, and increased promotion costs supporting return to care activities for our key growth drivers. The effective tax rate this quarter was 14.6%, up 1.3% from the same period last year, due to discrete items in the prior year. All together, we earned $1.31 per share, which is 27% higher. Before I get to our 2021 guidance, let me briefly remind you of the benefits we anticipate from the Organon spin-off. Now that the spin is complete, Merck is a more focused company and better positioned to unlock the full potential of our growth pillars and drive accelerated, profitable growth. We're very excited about what lies ahead, and looking toward 2024, we still believe our revenue potential is underappreciated. For 2021, health systems and patients have mostly adapted to the pandemic's impacts, and we expect this trend to continue. We're tightening and lifting our revenue outlook to a range of $46.4 billion to $47.4 billion, which works out to 12%-14% growth, and that figure includes a favorable currency effect of under 2% based on rates from mid-July. Demand underneath our growth pillars, along with solid commercial execution, gives us confidence that strong momentum will carry on through the rest of the year. We anticipate total revenues rising sequentially in every successive quarter. For gross margin, we're looking at 76% to 77%. Operating expenses should increase at a high single-digit rate, fueled by bigger investment in promotion and patient activation programs meant to speed up near-term business momentum, plus more R&D spending to move our promising pipeline forward and support durable long-term revenue growth. Our operating margin from continuing operations is going to come in below what it was as a combined company, though the guidance range we've given points to considerable operating leverage in 2021. We still anticipate operating margins above 42% in 2024, powered by faster revenue growth and careful investment in the business. We're expecting expense of roughly $300 million. For the full year, we anticipate a tax rate of 14.5% to 15.5%. We're assuming 2.53 billion shares outstanding. All told, we expect non-GAAP EPS between $5.47 and $5.57, which reflects 21%-23% growth; this range incorporates a favorable currency impact of about 2% at mid-July rates. When you think about your models and how revenues get allocated across products, two areas deserve attention: GARDASIL and Animal Health. Frank walked through the sharp acceleration in growth we expect from GARDASIL, and we likewise anticipate ongoing momentum in our Animal Health business. Our revised guidance also captures the advantages from the KEYNOTE-522 approval and, as a reminder, excludes any revenues from a possible molnupiravir launch. On capital allocation, we got a $9 billion cash distribution from Organon, and we plan to put it toward value-enhancing strategic business development opportunities that fit the parameters Rob laid out. If meaningful business development doesn't materialize, we'll give cash back to shareholders via share repurchases. We're still committed to investing behind our key brands and pushing our innovative pipeline ahead. Over time, we intend to raise our dividend payout ratio. In closing, as a leaner, more focused, and agile company, Merck is ready to seize the meaningful opportunities ahead and is better positioned to thrive in an ever-changing landscape. Merck continues to hold financial and operational strength, which we'll use to drive long-term sustainable growth and value creation for our patients and shareholders; with that, I'd now like to hand the call over to Dean.

Dean Li

executive
#5

Thanks, Caroline. It's great to be with you today to walk through how we've done over the last quarter. I'll go over the main regulatory milestones and clinical news, starting with oncology and then moving to the wider pipeline. As Rob pointed out, we're still seeing a lot of momentum in our oncology pipeline, and that puts us in a good spot, and it bears repeating that our aim is potentially to bring more than 90 approvals and new indications to patients by 2028. A report that came out recently from the American Cancer Society pointed to a sharp drop in deaths from lung cancer and melanoma between 2014 and 2018. Research advances, among them targeted therapies and immune checkpoint inhibitors, are one factor credited with that decrease. That report also points out that there's a pressing need to speed up the fall in mortality rates for breast, prostate, and other cancers, areas where Merck is only starting to have an effect. Our hope is that what we contribute, together with progress being made across the industry, will keep driving that decline. Importantly, over the last quarter we hit a number of milestones for therapies aimed at women's cancers. In triple-negative breast cancer, the most aggressive subtype of breast cancers, where treatment choices have historically been limited, I'm happy to report several advances that will expand what's available to patients. The first is FDA approval of a new indication in high-risk early-stage triple-negative breast cancer, supported by data from the pivotal phase III KEYNOTE-522 study, in which KEYTRUDA was assessed with chemotherapy as neoadjuvant treatment and afterward as monotherapy adjuvant treatment following surgery; those practice-changing event-free survival data were shared only two weeks ago, showing a striking 37% lower risk of progression that precludes definitive surgery, local or distant recurrence, a second primary malignancy, or death from any cause, compared with chemotherapy alone in these patients. On top of that, we reported positive, clinically meaningful top-line overall survival data from the phase III KEYNOTE-355 study, which assessed KEYTRUDA plus chemotherapy in patients with previously untreated metastatic triple-negative breast cancer whose tumors express PD-L1 with a combined proportion score of 10 or higher. That puts KEYTRUDA in position to become the first anti-PD-1 therapy combined with chemotherapy to demonstrate statistically significant overall survival in metastatic triple-negative breast cancer. We'll engage with regulators to broaden the current indication so it captures the survival benefit, and we intend to share the complete results before long; also in early-stage breast cancer, working with our partners at AstraZeneca, we presented data at ASCO from the phase III OlympiA trial, which assessed LYNPARZA as adjuvant treatment for certain patients with germline BRCA high-risk, HER2-negative early-stage breast cancer. Those findings clearly showed that LYNPARZA cut the risk of invasive breast cancer recurrence, second cancers, or death by 42%. The results will go to regulatory authorities around the world. The trial is still evaluating overall survival; also at ASCO, alongside our partners at Seagen, we shared further encouraging data from the HER2CLIMB study of TUKYSA in patients with early-stage HER2-positive breast cancers. It's evident that Merck is building a significant beachhead in breast cancer with a number of agents. What we're achieving for this group of patients facing a serious unmet need illustrates how we're pursuing growth into earlier treatment settings, and it reflects our firm belief that our oncology portfolio could transform how early-stage cancers are addressed. Progress is also happening in women's cancer as a whole. The FDA gave us approval for a broader indication covering the pairing of KEYTRUDA and LENVIMA to treat specific patients who have advanced endometrial carcinoma; working alongside our partners at Eisai, we presented findings from the confirmatory phase III KEYNOTE-775 study earlier in the year. We also saw favorable outcomes from the pivotal phase III KEYNOTE-826 trial, which examined KEYTRUDA together with platinum-based chemotherapy, with or without bevacizumab, as first-line therapy for patients whose cervical cancer is persistent, recurrent, or metastatic, irrespective of PD-L1 status. Both dual primary endpoints — overall survival and progression-free survival — were met by the trial. The results are going to be shared at a forthcoming medical meeting and filed with regulatory authorities. Among other FDA approvals during the quarter were two additional indications for KEYTRUDA. The initial one covers use alongside trastuzumab and chemotherapy as first-line treatment for patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma, drawing on findings from the phase III KEYNOTE-811 study. The subsequent approval broadened the indication for cutaneous squamous cell carcinoma among patients whose locally advanced disease cannot be cured through surgery or radiation. That came through accelerated approval, supported by a phase II KEYNOTE-629 study. Relying on phase III data from KEYNOTE-581 concerning first-line treatment of advanced renal cell carcinoma, the FDA additionally granted priority review, with a decision anticipated during the third quarter. Beyond the United States, the European Commission authorized a new indication for KEYTRUDA combined with chemotherapy in specific patients who have esophageal cancer or HER2-negative gastroesophageal junction adenocarcinoma, based on findings from KEYNOTE-590. In China, LYNPARZA received conditional approval for certain patients with metastatic castration-resistant prostate cancer whose disease progressed after earlier treatment with particular new hormonal agents. Among PARP inhibitors, this marks the first approval for advanced prostate cancer in China. At the ASCO virtual meeting as well, fresh data supporting KEYTRUDA's benefit in earlier lines of therapy was presented from the pivotal phase III KEYNOTE-564 trial, which looked at adjuvant treatment for certain patients with renal cell carcinoma. When given following surgery, KEYTRUDA showed a statistically significant and clinically meaningful 32% reduction in the risk of disease recurrence or death relative to placebo. Submissions will go to global regulatory authorities, and the trial will keep evaluating overall survival. Our strategy to bring KEYTRUDA's benefits to more patients is moving forward. That includes launching a phase III trial to assess a subcutaneous version of pembrolizumab combined with chemotherapy in patients who have non-small cell lung cancer. We think this new formulation might serve as a meaningful extra choice for patients. This trial is going to start patient enrollment shortly, and we anticipate seeing results around the beginning of 2023. And then, belzutifan is moving ahead nicely—we shared further phase II findings at ASCO, we're expecting the FDA to act by September, and a development effort involving three phase III trials in renal cell carcinoma is picking up speed. Switching over to the rest of our pipeline: after SARS-CoV-2 spread in India, we chose to provide access to molnupiravir in low and middle-income nations via voluntary license deals with a number of Indian generic drugmakers. The studies still running in India involve a distinct patient group, yet the data coming out of them gives us encouragement, and we're eager to keep contributing amid this crisis; our enthusiasm about molnupiravir's advancement and the results gathered so far has not faded. Together with Ridgeback Biotherapeutics, our collaborator, we disclosed that complete findings from the dose-finding stage of phase II/III research covering both outpatient and hospitalized individuals would be presented at the European Congress of Clinical Microbiology and Infectious Disease 2021. We're anticipating results from the phase III part of that trial sometime during October.

Dean Li

executive
#6

Also, we have now shared results from a fresh phase III trial that assessed molnupiravir as a means of post-exposure prophylaxis, and we expect data to be announced during the first half of 2022. When it comes to HIV, our islatravir development program keeps moving ahead — that is our investigational nucleoside reverse transcriptase translocation inhibitor. Findings from phase II that were presented at the International AIDS Society meeting a few weeks back went on supporting the safety and tolerability profile for oral islatravir taken once monthly in the PrEP setting. Enrollment of patients is ongoing across a range of populations and geographies in the phase III EMPOWER trial, and we are advancing studies that look at islatravir for both treatment and prevention. Turning to vaccines, I am happy to report that the FDA has approved VAXNEUVANCE, which is the first of a suite of promising pneumococcal conjugate vaccine candidates intended to prevent invasive pneumococcal disease in adults 18 years and older caused by 15 serotypes. Together with immune response data demonstrating that VAXNEUVANCE can sustain the progress achieved so far through non-inferiority to serotypes shared with PCV13, VAXNEUVANCE additionally produced a superior immune response compared with PCV13 for shared serotype 3, and for 22F and 33F, the 2 serotypes unique to VAXNEUVANCE. Such immunogenicity data put this vaccine in a position to provide a significant new choice for protecting adults against invasive pneumococcal disease. We anticipate further dialogue with the ACIP, which will include talking over the positive results achieved via our robust development program, examining a wide range of adult populations and clinical circumstances, among them adults at increased risk. Extending our clinical evidence for VAXNEUVANCE, we also shared that two of our phase III pediatric studies reached their primary immunogenicity and safety endpoints, supporting potential use in healthy infants who may have already begun a pneumococcal vaccination series with PCV13, and in a catch-up setting for healthy children who either have not gotten pneumococcal vaccine or have gotten a full or partial regimen with lower valency pediatric PCVs. We still expect data from our phase I/II program assessing V116, our adult-focused vaccine, to be announced later this year. In closing, I stay enthusiastic about the advances in our broader pipeline and the work coming out of Merck Research Labs that helps improve options and treatments for diseases affecting people around the world. We keep executing our strategy with speed and urgency so as to harness the benefits of our cancer therapies for as many patients as possible, while pushing forward a broad pipeline of promising vaccines and therapeutic candidates. At this point I will hand the call back over to Peter.

Peter Dannenbaum

executive
#7

Thanks, Dean. Mary, could you get the Q&A portion underway? So that we can fit in more people asking questions today, we're requesting that every analyst stick to a single question. Appreciate it.

Chris Schott

analyst
#8

Alright, thank you very much for that. For my single question, I suppose it's a broader one aimed at Rob. Could you expand a bit further regarding the business development landscape? Now that the Organon transaction is behind you, I believe you're emphasizing R&D as a priority, sort of prioritizing bringing additional innovation into the company. What's your thinking around deals that might speed up the company's investment in oncology, where clearly there's a competitive strength, as opposed to greater diversification across therapeutic areas? Perhaps you could just outline the advantages and disadvantages when you weigh and consider bigger transactions against a string of smaller ones? I realize you're evaluating everything, but I'm simply attempting to gauge, all else being equal, whether there's a leaning in one direction or another right now. Many thanks.

Rob Davis

executive
#9

Of course. Yes, I value that question, Chris, and good morning. Like I mentioned during my prepared comments, business development has our full attention, and we acknowledge that it's a necessity for us. Our pipeline requires strengthening, though I'd also like to emphasize — and I hope this came through in what Dean just described — that our internal pipeline is robust as well, and I don't want that to be overlooked. We genuinely hold a great deal of conviction about what we're capable of advancing across the full range of oncology assets, plus assets beyond oncology and vaccines — clearly in HIV, every one of the areas Dean mentioned. Having said that, we understand more must be added, and we must expand on what exists, and that's where our attention is firmly placed. Obviously, we view ourselves — and I noted this during my prepared comments — as having real strength in oncology. That strength is something we intend to grow, and in fact we envision ourselves as an organization that in time can become a wide-ranging participant throughout oncology, truly capitalizing on the cornerstone position KEYTRUDA gives us, while reaching far past KEYTRUDA, and that process has already begun. When it comes to business development, I'll always examine that, because at present, looking at where one of the biggest remaining unmet needs persists — even with the progress achieved through KEYTRUDA and other novel agents, which are extraordinary in what they provide for patients — the reality remains that most patients still lack a solution for the cancers confronting them. This remains a domain of unmet need. An enormous amount of science is underway in this domain, concentrated here, and as I mentioned, we possess the strength to capitalize on KEYTRUDA's position and truly the data in our possession throughout our oncology area, enabling us to be a distinctive and, I believe, singular observer of this field, capable of choosing the finest opportunity. That's going to be a priority, yet I also understand we must go beyond just that; balance is required, and we're examining areas beyond oncology too. I'd want to see us pursue things in both. Establish the solid base, keep leading in oncology, capitalize on the data we hold there, while seeking where we can achieve balance and strengthen the portfolio in areas outside. Regarding the second portion of your question, about the advantages and disadvantages of large versus small deals. Ideally, the place where we believe maximum value gets created is when you acquire assets that are somewhat earlier in development, where our clinical expertise can be applied to guide them through and genuinely create added value. Those represent the deals we've traditionally pursued, yet doing larger deals is not something we've ruled out. Like I've said all along, and my view hasn't changed, the priority is locating the right science — science comes first as the essential piece, with the portfolio's impact shaping our thinking, since that's where we think we bring value. Should we identify such deals, we'll act on them, regardless of size. Obviously, the very large deals built around synergies are an area we still feel no need to enter. Our own pipeline, plus what we're able to bring in across the portfolio through science-focused deals, gives us sufficient firepower, in my view. At this point, there's no reason for us to pursue those big kinds of deals.

Peter Dannenbaum

executive
#10

Thank you, Chris. Next question, please.

Umer Raffat

analyst
#11

Hey everyone, appreciate you letting me ask. I figured I'd zero in a bit on molnupiravir, given that it's the study that's on deck, and presumably it's also the largest swing factor when it comes to the figures for next year, the way we see it. Here's what I want to know: regarding that 0.5 to 0.7 log antiviral effect you're observing, what sort of reactions are you getting about the size of that viral load reduction? And what reactions have there been concerning the clinical benefit seen with it in the MOVe-OUT trial? The reason I'm asking is that it appears that despite the fact you're restricting your primary analysis to patients who were enrolled in under five days, I still believe a decent number of seropositives are baked into how you're examining the data. I sort of suspect seronegative might be the group where the signal will come through most cleanly. I'd be really interested to hear. Thanks.

Dean Li

executive
#12

Yes, this is Dean, and I'll address that. Our work with molnupiravir is moving forward through a phase III clinical trial. The study centers on the outpatient setting, and our emphasis is on patients at high risk. Why do I stress this? Because what you've noted regarding viral load and similar matters are indeed significant observations. Still, I'd point out that under the U.S. regulatory system at least, viral load isn't the key concern; what matters is whether clinical events can be influenced. So concentrating on high-risk patients is the essential priority we've chosen. Regarding this study, its primary completion date is stated as October, and we're quite excited about the way it's going, with hopes of seeing results in the months ahead. Let me stress that this is a blinded, worldwide study centered on high risk, and since the pandemic continues to move around, it involves not only the U.S. and the EU but also key nations such as South Africa, Brazil, and Colombia. Those nations matter enormously for demonstrating not merely a decrease in viral load but a substantial effect on clinical outcomes. That is what this trial must demonstrate.

Peter Dannenbaum

executive
#13

Great. Thanks, Umer. Next question, please.

Louise Chen

analyst
#14

Hello, and thank you for allowing me to ask. What I wanted to know is how we ought to view the chances you have to expand margins. I realize you've provided some guidance covering a longer horizon, but if we take the next 12 months, for example, how might that unfold? Thanks.

Caroline Litchfield

executive
#15

Louise, it's Caroline here. I appreciate the question. Let me begin by saying our pipeline is rich, so as an organization, our attention is on increasing spending to back the near-term and long-term opportunities before us, and that will let us generate revenue growth over the long term. With that said, we likewise anticipate delivering margin expansion. A few separate factors will produce that margin expansion. Revenue growth will be one source; another will be a shift in the mix of our products. Efficiencies throughout our operations will contribute as well, along with our pledge to achieve $1.5 billion in operating efficiencies across the three-year period. Last, we anticipate a margin increase in 2024 stemming from the step-down of royalties tied to KEYTRUDA and GARDASIL. When I consider margin expansion, the midpoint of our guidance range for this year presumes a 2 percentage point rise in margin. Looking ahead to the years to come, I expect that margin expansion to keep growing.

Peter Dannenbaum

executive
#16

Excellent. Appreciate it, Louise. Let's take the following question.

Terence Flynn

analyst
#17

Excellent. Thank you for fielding this one. It has two parts. Rob, I suppose I'm simply wondering whether you have established any in-house deadlines regarding how the Organon funds get used, and I'd like to hear your most current perspective on what assets are worth. After that, Dean, clearly there's been an enormous amount of advancement on new platforms across the past 12 to 18 months, and Rob, you mentioned a few of those, but is there any in particular that strikes you as capable of being as revolutionary as antibodies proved to be 20 years back? Thanks.

Rob Davis

executive
#18

Terence, I appreciate that. Going forward, we are searching actively and intend to act quickly. I'd rather not attach a deadline to how quickly, since clearly a portion of this hinges on market conditions, plus where assets sit within their own life cycle and the conversations we're currently having. At this moment our attention is on locating approaches to supply the pipeline via BD, yet there's no time constraint attached. What I believe Caroline is truly getting at is that in the end, should those opportunities fail to materialize, sitting on the cash indefinitely isn't something we'll do. I want to ensure BD gets prioritized ahead of us reaching that conclusion.

Dean Li

executive
#19

When it comes to your second question, the list of technological advances is so long that no matter what I mention, I'll leave something out. I'll keep my focus away from platforms, mostly. Data platforms are seeing a great deal of activity, and I consider that critically important, but so are what I'd describe as technology platforms that matter for producing molecules like antibodies, as you put it. Obviously, protein engineering is seeing lots of activity. Obviously, protein degradation is seeing activity. Obviously, antibody drug conjugates are seeing activity, and every one of those interests us. One of the key questions people tend to consider, particularly regarding our identity as a vaccine company, concerns mRNA, and truly the achievement of a monovalent SARS-CoV-2 vaccine is something that has shown the speed we had always appreciated, plus the scalability. We were among the earliest to put money into mRNAs for vaccines, for IV, and for oncology. So we're applying some of those teachings and giving priority to programs where we believe mRNA will matter. I want to stress, though, that for programs like pneumococcal vaccines, I don't believe mRNA vaccines are the right approach there. For complex multivalent vaccines with deep and established clinical benefits like GARDASIL, I'm not so certain that's where I'd push an mRNA vaccine. Beyond infectious disease, we keep up a highly productive collaboration with Moderna in oncology. The area where we exercise more caution is beyond vaccine applications. We observe that technology's progress with interest.

Rob Davis

executive
#20

Terence, I owe you an apology — I realize I left the valuation portion of your question unanswered. In terms of what the market is showing us, valuations generally remain full. There's obviously a tremendous amount of money moving into biotech, as we're all aware. That clearly creates a challenge. I'd simply remind you that we understand we have to be suitably aggressive when pursuing these opportunities. My view remains that when we lean into the places where we see differentiated opportunity, grounded in our scientific assessment of the landscape, we can continue generating value even as we add to the pipeline strategically — and that is truly our focus.

Andrew Baum

analyst
#21

Thanks, Terence. Let's take the next question. From where the market sits, the pipeline gets no credit the way you give it credit — that includes products like islatravir — and without pointing out what everyone already knows, attention stays on the LOE 2042 toward the close of this decade. My basis for saying so is this: in the past, Rob, you pointed out that Merck understands it must pull back the curtain on its pipeline assets more than it has in the past. You have quite sizable late-stage programs in TIGIT, ILT4, CTLA-4, and others. At what point should we look for that curtain to come up? And one more thing, a yes-or-no item. Merck has a pro-drug of islatravir that they are moving into the clinic. In your view, does it infringe on your intellectual property? Thank you.

Rob Davis

executive
#22

Andrew, we're going to give that a shot. Honestly, it arrived quite garbled. The first portion, I believe, concerned pipeline transparency and when we'll be sharing additional details on that front. Like I mentioned, that's something we're focused on. We did exactly that with the broader HIV portfolio presentation, plus the recent effort to offer some visibility into our wider early-stage oncology pipeline beyond KEYTRUDA. My sense is that sometime near the close of the year, we intend to hold another session. Naturally, we'll consider it as we head into next year. The things we'd like to put a spotlight on going forward — clearly, as I noted, cardiometabolic is somewhere we're building greater conviction and interest. We have strong enthusiasm for our wider vaccines portfolio and perceive substantial opportunity in that space. Those are a few places we'll concentrate on down the road; and then, if I understood correctly, you were also wondering whether we'd encountered a pro-drug IP problem with islatravir. I'll hand that to Dean, assuming he knows, if I've captured your question properly.

Dean Li

executive
#23

Okay, so first off, islatravir is a core building block you can develop around — that's the basis of our approach: used alone for prevention, and in combination when it comes to treatment. As I see it, the interest in islatravir confirms just how strongly we believe in this mechanism and in islatravir itself. Regarding the legal situation, we feel quite good about where we stand with islatravir. I'd rather not comment specifically on freedom to operate and that sort of thing as it relates to other companies' compounds, not until we can see the structural details and so forth. Our confidence is high when it comes to our investment and our patent position with islatravir.

Peter Dannenbaum

executive
#24

Thanks, Andrew. Let's take the next question.

Daina Graybosch

analyst
#25

Hello, and thanks for taking this. I want to ask something about pneumococcal. Could you share what you see as your base case and your best case for the ACIP meeting in October, since the preview analysis from June didn't take into account certain advantages of your vaccine, including around serotype 3, as well as other strengths?

Dean Li

executive
#26

Alright, I'll start by taking that one, and afterward I'll hand things over to Frank. Our confidence is high when it comes to the clinical program for V114, also known as VAXNEUVANCE, and in the robustness of the data underpinning the filing. That data demonstrated wide-ranging protection against serotypes that cause illness, plus better immune performance for the serious serotypes that stick around; this is going to be a key point. Serotypes aren't all the same. Some of them matter much more than the rest. At the ACIP, grasping the epidemiology and how one reasons through that is going to matter a great deal. We've now shown that the immune response data truly indicates non-inferiority for serotypes shared with PCV13, and superiority for three that carry substantial importance from an epidemiologic perspective. Another matter I'd like to raise as well is that we're also moving V114, or VAXNEUVANCE, forward — not only where adults are concerned, but we're pushing it forward aggressively on the pediatrics side too, and we're additionally advancing a more tailored adult-focused vaccine, V116, with data we hope to share at some point across the coming year or so. Frank?

Frank Clyburn

executive
#27

Alright, Daina, here's what I'd say. First off, we're thrilled about the overall chance we've got with our pneumococcal business. As for your ACIP question, we're still waiting to get a clearer picture of what the upcoming guidance will actually be for each of the vaccines — PNEUMOVAX, VAXNEUVANCE, and PREVNAR 20. You've seen some of what came out in June. Right now, Daina, there could be a move toward favoring certain newer pneumococcal vaccines if an age-based recommendation is what they choose. They're examining multiple populations as part of their recommendations, and at present our focus is squarely on making certain they grasp our data and what our products bring, across both PNEUMOVAX 23 and VAXNEUVANCE. Should PNEUMOVAX face some degree of risk, as I said, we'll just have to watch how things unfold. I'd also point out that for us, particularly with VAXNEUVANCE, as Dean described, this is kind of just the start; we believe our adult offering is highly competitive. The pediatric opportunity has us very enthusiastic, and you heard Dean reference our two phase III trials in pediatrics too, while we keep working on developing V116 for adults, plus V117. Looking at the pneumococcal franchise as a whole, and I'd call vaccines a growth pillar for this company, we have strong confidence in ongoing vaccines growth for the company, both in the near term and over the long term.

Peter Dannenbaum

executive
#28

Thank you, Daina Graybosch. Next question, please.

Geoff Meacham

analyst
#29

Hello there, everyone. Morning to you, and I appreciate the inquiry. Rob, I’d like to pose one more question regarding strategy, right after the spin has been finalized, to understand what boundaries exist as you consider BD. Specifically, would broadening the revenue mix so it’s less dependent on oncology be a higher priority than the operating margin growth that’s anticipated? To be more specific about therapeutic areas, I realize you follow where the science leads, but how do you view the orphan drug space or growing your presence in neuroscience, given that the FDA landscape seems more favorable now? Thanks.

Rob Davis

executive
#30

Yes. Geoff, thanks for bringing that up. When we consider business development and where it fits with the operating margin targets we've set for the company, I have a few things to say. First, it matters to note that, as I mentioned, we're convinced that in time we need a portfolio that's more balanced, and we want to add that diversification. Let me clear up one thing about what you said. To me, diversifying away from KEYTRUDA is not the same as diversifying away from oncology. Oncology, clearly, is a wide-ranging space, and like I said before, enormous unmet needs remain there. In that space we can take advantage of the strength KEYTRUDA gives us, the foundational position we hold, the data we have, the insights we gain from essentially being tested, whether in combination with or against just about every agent that exists. Expanding and diversifying across oncology more broadly is, I believe, a key objective for us going forward. I also think we ought to pursue other therapeutic areas. Vaccines are an area of strength for us; we're exploring there. Cardiometabolic is one we've named, and actually, Dean can speak to neuroscience, but we do have a number of early-stage programs currently underway in neuroscience. That has us excited. As for your question about our priorities, above all else, my priority is growth that's sustainable over the long term, and in our line of work that comes down to innovation and putting money into science, so that will always come first for us. My belief is we can achieve that while also expanding operating margins for the business. If I had to choose between cutting costs and funding growth, funding growth is what I'd always choose.

Dean Li

executive
#31

I'll try to address what you asked regarding neuroscience and orphan disease. If we're talking about rare diseases, I'm actually a fan, since that approach gives you a fast route to establishing proof of concept and to moving with speed. When you've reached that point, being able to grow outward from such a foothold matters a great deal. I stress this because a deal such as belzutifan, even though it sits in oncology, is essentially a rare disease endeavor, with the potential to extend into larger cancer populations. Whether that plays out in cancer or in non-cancer assets, pathways, and opportunities, that's a model we're eager to repeat. On the neuroscience side, you're correct. The FDA has recently made moves, and biomarkers have grown in significance. I'd like to set the record straight, though: the value of biomarkers has to be weighed against the value of demonstrating shifts in meaningful clinical events for patients. Things have shifted. We're keen to figure out the best way to leverage that biomarker momentum, particularly, for instance, with our phospho-tau program, which we're quite excited to push forward. Given the evolving landscape, how that ought to proceed and how we should approach, say, tau biomarkers within that clinical strategy is something we're intensely focused on. We have additional neuroscience programs. MK-8189 is in phase II for schizophrenia. We're moving MK-1942 ahead for treatment-resistant depression. The changing regulatory environment in neuroscience matters. We factor it in, it shapes how we steer through this field and speed up the programs we have, and it likewise alters how we evaluate business development.

Peter Dannenbaum

executive
#32

Thanks, Geoff. We know it's 9 o'clock already. We're happy to run a few minutes over so we can take a few more questions. Mary, let's have the next question.

Ronny Gal

analyst
#33

Morning, and thanks for fitting me into the schedule. I'd like to hear a bit more about applying mRNA in a multivalent format. You seem to acknowledge that this is a tough nut to crack. Is it something that's theoretically unachievable, or is it simply a matter of engineering — figuring out how to make messenger RNA vaccines work in a multivalent way?

Dean Li

executive
#34

I'll field that one. When it comes to multivalency, the greater the number of valences you build into any vaccine, the more complex things get. Then there's the question of the dose required, plus what we refer to as reactogenicity each time you introduce an additional component; I'd be wrong to claim that any of this can't be done. Science and technology evolve. What I was attempting to frame is that certain areas exist where, in my view, the field would move quickly with mRNA to achieve clinical impact, while in other areas, I believe additional discovery and technological development will draw heavy interest toward surmounting some of those early hurdles.

Peter Dannenbaum

executive
#35

Thanks, Ronny. Let's take the next question.

Mara Goldstein

analyst
#36

Oh, excellent. I appreciate you taking my question. Mine concerns pricing. As we moved into the start of this year, one point Merck raised was that pricing might keep being a significant problem for the pharma sector, and that the strain would just grow. A few days back, we witnessed what I'd call some vague gesturing, I think, from the Biden administration, discussing the federal government's ability to negotiate prices within Medicare. So as 2021 wraps up and we head into 2022, I'm curious what the company thinks about pricing.

Rob Davis

executive
#37

Yes. Thanks for that. I'll respond to it. Obviously, we still anticipate seeing continued pressure when it comes to pricing, and the conversations you're referring to—taking place at this moment with Congress, plus with the Biden administration as well—only underscore that this threat remains present. As we concentrate on this, a few things stand out. First, going forward, every expectation we've shared previously regarding our company's growth already factors in that we'll encounter significant price pressure; our belief remains that volume, rather than price, will be the bigger driver of our growth, and that matters when you consider the company's long-term risk position. Looking ahead across the coming 5+ years, we've largely removed risk from our revenue goals, and I believe we can get there no matter what happens with price. Beyond that, from a policy standpoint, we're very open to sitting down with the U.S. government and discussing the best path toward lowering what patients pay out of pocket. That goal comes first for us. We genuinely see that need and are ready and eager to collaborate with them on it, while also making sure we safeguard innovation, since we need to keep delivering new advances for future patients who will depend on them. The entire COVID-19 experience has demonstrated why a strong, innovative industry matters, because when the need arises, it's crucial that it exists here in our country, and that we can put money behind it and propel it forward. That's what we're focused on. Once again, the real question is where we can find reductions in out-of-pocket cost—any approaches, whether legislative or otherwise, that fail to pass along some form of savings into the patient's pocketbook are something we oppose.

Frank Clyburn

executive
#38

(Peter Dannenbaum): Thanks, Mara. Let's take the next question. (Carter Gould): Morning. Appreciate you taking my question. I'd like to discuss how things went in China. You posted a really solid quarter there. I was hoping for a bit more detail on what exactly fueled those results. Did GARDASIL play the bigger role, or was it LENVIMA? My reason for asking is really what you've said about the GARDASIL results you're expecting in the second half, plus the extra supply capacity that's coming online. Any detail on those points would be useful. Thank you. (Frank Clyburn): Hello, Carter. This is Frank. China's growth was extremely robust this quarter. If we strip out foreign exchange, I believe it came to 42%; GARDASIL was truly the engine behind it. As we've said, that's very strong growth, and we expect it to keep going going forward, given the large patient numbers and the fact that GARDASIL's penetration in China remains comparatively low. We obviously see opportunities in that market. I'd also point out that oncology showed very strong growth as well, with LENVIMA, LYNPARZA, and KEYTRUDA all growing very strongly this quarter, so several of our growth drivers contributed. Beyond that, JANUMET and diabetes in China are also still delivering strong growth. We expect that growth to continue. This connects quite well with our strategy, where we made a pivot toward putting more emphasis on our innovative product portfolio for China, and that's the reason we have a lot of confidence in China's future growth.

Peter Dannenbaum

executive
#39

Thank you, Carter. We have time for one last question.

Steve Scala

analyst
#40

Oh, thanks a lot. Could you give us the latest on the anti-ILT4 antibody? Quite a few new trials have kicked off lately. What does Merck find appealing about this target? Thank you.

Dean Li

executive
#41

Okay, Dean here. We're keeping a very close eye on ILT4 within our own pipeline. This is something we started ourselves after examining patient data from trials involving pembrolizumab, focusing on individuals who responded—and even more crucially, figuring out what mechanisms might explain that response. Another thing I'd stress is that ILT4 is, in a way, a checkpoint inhibitor, though it doesn't act on T cells. People have long debated whether a different category of immune cells—myeloid cells, for instance—might matter enormously. That's reason number two we're so intrigued. Honestly, my third point is that while all this makes for fascinating science and a solid hypothesis, at the end of the day, we need clinical trials demonstrating it; we're pushing trials forward for ILT4, and I believe other companies' willingness to follow our lead on ILT4 stems from watching us move it ahead, and we trust our data will back that advancement, and we'll simply have to observe what the benefit turns out to be; this is a highly differentiated first-in-class mechanism—not only the molecule, but also the cellular strategy for how we're broadly taking on cancer.

Peter Dannenbaum

executive
#42

Thanks, Steve, and thanks to everyone for the truly excellent questions you raised today. I'll hand things over to Rob, who has a few final comments.

Rob Davis

executive
#43

Okay, thank you, Peter. As we've gone over during this session, I hope what comes across is that there are substantial possibilities ahead of us when it comes to expanding and creating value. I'm dedicated to seeing that through, and I'm aware my team shares that dedication, and more than that, we have confidence that we can pull it off. Merck is an organization that holds real importance, and when we reflect on that, we recognize change is necessary, yet we also occupy a distinctive role globally, and we remain devoted to serving the patients who depend on us, and honestly, to produce the kind of lasting growth that I'm certain our investors are looking for, and I believe we'll achieve exactly that. I'm eager to share news about how we're progressing down the road, and I hope everyone has a wonderful remainder of the day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Merck & Co., Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Merck & Co., Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck & Co., Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.